Papers/PMID:35685602
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.
International journal of clinical practice2022The record
3 findings drawn from this paper, on 1 compound across 3 endpoints, 2 of them null.
What it reported
How to read these marksWhat moved
1 finding
resveratrol — decreases diastolic blood pressure (setting unspecified)
LikelyGrade B, Likely. Human evidence, limited replication or design limits.Findingreplicated ×1“The results illustrated a significant reduction in the DBP by resveratrol after removing these studies (WMD: −3.55 mmHg, 95% CI: −5.18, −1.93; P < 0.0001;.”
Quoted verbatim from Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Dose
- 8.1-3000 mg/day resveratrol across the pooled trials
- Population
- Adults with type 2 diabetes; secondary endpoint, pooled after excluding two high-heterogeneity trials, resveratrol vs placebo
Effect -3.55 mean difference, 95% CI -5.18 to -1.93
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.2022PMID:35685602
What did not
2 findings
resveratrol — no detected effect on HDL cholesterol
Well establishedGrade A, Well established. Replicated human trial evidence, consistent direction.FindingNull resultreplicated ×1“Compared with the placebo, resveratrol did not improve HDL-C levels (WMD: −1.05 mg/dL, 95% CI: −2.44, 0.33; P=0.14;.”
Quoted verbatim from Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Participants
- 837
- Dose
- 8.1-3000 mg/day resveratrol across the pooled trials
- Population
- Adults with type 2 diabetes; secondary endpoint, 14 pooled RCTs, resveratrol vs placebo
Effect -1.05 mean difference, 95% CI -2.44 to 0.33
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.2022PMID:35685602
resveratrol — no detected effect on fasting blood glucose
LikelyGrade B, Likely. Human evidence, limited replication or design limits.FindingNull result“The results indicated that resveratrol did not improve FBG levels versus placebo (WMD: −3.54 mg/dL, 95% CI: −12.45, 5.38; P=0.44;.”
Quoted verbatim from Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.. - Study
- meta-analysis
- Participants
- 1,151
- Dose
- 8.1-3000 mg/day resveratrol across the pooled trials
- Population
- Adults with type 2 diabetes; whole-population pooled estimate across all 19 RCTs, resveratrol vs placebo
Effect -3.54 mean difference, 95% CI -12.45 to 5.38
Effects of Resveratrol on Metabolic Indicators in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis.2022PMID:35685602